Total Hip Arthroplasty (THA)
Conditions
Brief summary
The primary objective of this trial is to determine the implant survival at 1 year of follow up in a population of patients undergoing primary Total Hip Replacement with MFinity Collared Femoral stem and to test its non-inferiority compared to other cementless implant (as reported by the EPRD registry).
Detailed description
This prospective study aims to assess the clinical and radiographic outcomes of patients undergoing THA with implantation of MFinity femoral stems to determine the safety and performance of the implant in comparison with registry data for uncemented THA. Participants will be informed about the study, both orally and in writing, during a preoperative visit. The investigator will answer any questions that may arise and will collect the informed consent. During the study, enrolled participants will be able to withdraw at any time and for any reason. The study is conducted according to the following schedule: * V1 : Inclusion during a preoperative visit * V2: Surgery * V3: Follow-up visit at 6 week post-surgery * V4: Follow-up visit at 3 months post-surgery * V5: Follow-up visit at 12 months post-surgery * V6: Follow-up visit at 24 months post-surgery The following data will be collected: * Rate of complications, Device Deficiencies and Adverse Events * HHS and FJS at 6 weeks, 3 months, 1 and 2 years postoperatively * Radiologic evaluations at immediate postoperative assessment, 3 months, 1 and 2 years postoperatively A web-based data collection tool will be used as Electronic Data Capture (EDC). All the information required by the protocol will be collected in electronic case report forms (eCRF). The statistical analysis will be performed according to a pre-established statistical analysis plan. Missing values will not be replaced by estimated values but will be considered as missing in the statistical analysis.
Interventions
DEVICEMfinity collared stem
The MFinity Femoral Stem is intended for cementless use in total or partial hip arthroplasty to replace the native femoral neck for primary or revision surgery. The devices are made of Ti6Al7Nb and coated in the proximal end of the shaft with TiGrowth-C titanium. The thickness of the Ti coating is 700μm while the thickness of the HA coating is 80μm.
Sponsors
Medacta International SA
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients undergoing elective primary total hip arthroplasty for primary osteoarthritis, who are suitable for implantation of a cementless femoral stem according to the MFinity femoral stem Instructions for Use * Skeletally mature adult aged 18 years and older at the time of enrollment. * Ability to give informed consent. * Patient is informed of the conditions of the study and is willing to participate for the length of the prescribed follow-up period.
Exclusion criteria
* Not meeting the inclusion criteria. * Active infection within the affected hip joint. * Previous total hip replacement or hip fusion of the affected hip joint. * Neuromuscular or neurosensory deficiency limiting the ability to evaluate the safety and effectiveness of the device. * Bone condition that may compromise the stability of the implant * Known allergy or hypersensitivity to the implant material * Immunologically suppressed, or receiving steroids in excess of physiologic dose requirements. * For women of childbearing potential\*: a positive pregnancy test * Patients with severe osteoarthritis in the contralateral hip or other joints that may interfere with the assessment of study outcomes. * Patients who have previously participated in this clinical trial. * a woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Women using one of the following birth control methods are not considered of childbearing potential: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable),intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomised partner, and sexual abstinence.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Implant survival rate (%) assessed by Kaplan-Meier analysis at 1 year | 1 year | The survival rate according to a Kaplan Meier curve. The Kaplan-Meier method calculates the survival of the prosthesis by measuring the fraction of living subjects during a period after the procedure. Each time an expected event occurs (revision of the prosthesis, patients lost to follow-up, death, etc.), the probability of implant survival changes. This information is used to estimate the performance of the prosthesis. During the study, the number of stem revisions and the number of patients who died or were lost to follow-up will be collected to calculate the probability of survival. The time of occurrence will be recorded for each event. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Implant survival rate (%) assessed by Kaplan-Meier analysis at 2 years | 2 years | The survival rate according to a Kaplan Meier curve. The Kaplan-Meier method calculates the survival of the prosthesis by measuring the fraction of living subjects during a period after the procedure. Each time an expected event occurs (revision of the prosthesis, patients lost to follow-up, death, etc.), the probability of implant survival changes. This information is used to estimate the performance of the prosthesis. During the study, the number of stem revisions and the number of patients who died or were lost to follow-up will be collected to calculate the probability of survival. The time of occurrence will be recorded for each event. |
| Harris Hip Score | Pre-op, 6 weeks, 3 months, 1 and 2 years | Evaluation of the Harris Hip Score The Harris Hip Score (HHS) items include an analysis of the operated hip according to pain, function, mobility, stability and deformity analysis. The Harris Hip Score will be used to assess the patient's subjective and objective improvement in the above criteria. The usefulness of this score has been studied to estimate the clinical results after THR, it is a reference score in the field of orthopedics. The Harris hip score is scored from 0 (worst functional outcome and maximum pain) to 100 points (best functional outcome and least pain). |
| Forgotten Joint Score-12 (FJS-12) | Pre-op, 6 weeks, 3 months, 1 and 2 years | Evaluation of the Forgotten Joint Score TheForgotten Joint Score-12 (FJS-12) is a patient-reported outcome measure assessing patients' awareness of the artificial joint during activities of daily living. The questionnaire consists of 12 items, each scored on a 5-point Likert scale (0 = never aware, 4 = mostly aware). Raw scores are summed and linearly transformed to a 0-100 scale, with higher scores indicating less joint awareness and therefore a better outcome. |
| Incidence of device deficiencies | From surgery to 2 years post-operatively | Number of device deficiencies reported during the study. Device deficiencies will be documented by the investigator using the dedicated device deficiency reporting form. |
| Incidence of adverse events and serious adverse events | From surgery to 2 years post-operatively | Number and percentage of adverse events (AEs) and serious adverse events (SAEs). Events will be recorded by the investigator on the AE/SAE reporting form, classified for seriousness, severity, causality with the device and/or procedure, and outcome. |
| Radiological analysis | 3 months, 1 and 2 years postoperatively | Proportion (%) of radiographic findings (including radiolucent lines, stem subsidence, stem tilt, cup migration, endosteal cavitations, ectopic ossification, and signs of loosening, migration or osteointegration) assessed qualitatively and/or semi-quantitatively on standard anteroposterior (AP) and lateral hip radiographs, per standard of care. Findings will be reported descriptively at each time point. |
Contacts
CONTACTMarco Vigano'
PRINCIPAL_INVESTIGATORFrans-Jozef Vandeputte
Ziekenhuis Oost-Limburg AV, Synaps Park 1, B-3600 Genk, Belgium
Outcome results
None listed